ILLUMINA, INC. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Illumina reported Q3 2026 revenue of $1.13B (up 4.2% YoY), beating guidance with 27.0% GAAP operating margin and $1.43 diluted EPS. The company raised FY2026 guidance to $4.64–$4.66B revenue (from $4.60–$4.64B) and $5.40–$5.45 non-GAAP diluted EPS (from $5.30–$5.40), citing strong clinical demand and robust NovaSeq X instrument placements. Free cash flow was $378M in Q3 2026 vs. $253M prior year; cash position remains solid at $1.34B.
Why this rating
Moderate: 4.2% organic revenue growth is solid but not exceptional for a genomics leader. Guidance raise of $40–60M revenue (0.9–1.3% of $4.64B midpoint) and $0.10 EPS upside (1.9% of $5.425 midpoint) are meaningful but incremental. Material tariff refunds ($79M benefit in Q3) mask underlying operational dynamics. No major M&A, restructuring, or strategic shift disclosed.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.